-+ 0.00%
-+ 0.00%
-+ 0.00%
Eli Lilly to Hold Clinical Data Presentations on Weight Loss Drugs in US
Share
Listen to the news
06:26 AM EST, 11/15/2026 (MT Newswires) -- Eli Lilly (LLY.SW, LLY.F) will present its clinical data for trials that involve tirzepatide, orforglipron, retatrutide, and an eloralintide combo at the three-day ObesityWeek 2026 event in Washington, US. The pharmaceutical giant said Nov. 14 that the oral talks will cover the EloraTZP phase 2 study, the Triumph-1, Triumph-2, and Triumph-4 trials, as well as the phase 3 study for retatrutide and Zepbound. Additionally, the company will discuss its survey results for orforglipron and its exit interviews for the phase 2 study for eloralintide.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending